Supermicro Liquid-Cooled AI SuperClusters Will Power Large-Scale AI Data Center in Japanby June 3, 2024PR Newswire
A Remarkable 97.98% Recovery Rate: RSMC’s Outstanding Data Ignites New Fertility Trends in Japanby June 3, 2024PR Newswire
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancerby June 3, 2024PR Newswire
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meetingby June 3, 2024PR Newswire
GMM Music Announces Strategic Partnership with Tencent Music Entertainment Group and Tencent, with a Strategic Investment Valuing GMM Music at $700 Million USDby June 3, 2024PR Newswire
Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meetingby June 3, 2024PR Newswire
TalentCorp Leverages Malaysian Expertise Abroad: Announces Grant for Tokyo-Based Malaysian Researchers for Conference Collaborationby June 3, 2024PR Newswire
MSI Unveils New AI and Computing Platforms with 4th Gen AMD EPYC™ Processors at Computex 2024by June 3, 2024PR Newswire
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imagingby June 3, 2024PR Newswire
Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and USby June 3, 2024PR Newswire
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitisby June 3, 2024PR Newswire
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical Universityby June 3, 2024PR Newswire
เปิดตัวกล้อง DS362 Time of Flight Camera พลิกนิยามการเฝ้าระวังความปลอดภัยโดยยึดความเป็นส่วนตัวเป็นสำคัญby June 3, 2024PR Newswire
MTN Japan Deploys FutureDial NDSE™ Solution for Automating the Data-Clearing and Refurbishing of Used Networking Equipment for Resaleby June 3, 2024PR Newswire
Darren Bishop Joins TradeFlow Capital Management as Head of Strategic Partnerships (UK/Europe)by June 3, 2024PR Newswire
Kerry Logistics Network Commended for Comprehensive Climate Disclosure at the HKQAA Hong Kong Green and Sustainability Contribution Awards 2024by June 3, 2024PR Newswire
LOTTE rent-a-car employees recommend ‘Jeju Island’ as a domestic travel destinationby June 3, 2024PR Newswire
Kerry Logistics Network Named Global Logistics Company of Excellence by Hong Kong Economic Journal Corporate Brand Awards of Excellence 2024by June 3, 2024PR Newswire
เลนนี แครวิตซ์ ขึ้นแสดงโชว์สุดยิ่งใหญ่ เปิดการแข่งขันยูฟ่าแชมเปียนส์ลีกนัดชิงชนะเลิศ นำเสนอโดย PEPSI®by June 2, 2024PR Newswire
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®by June 2, 2024PR Newswire
Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479by June 2, 2024PR Newswire
ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024by June 2, 2024PR Newswire
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meetingby June 2, 2024PR Newswire
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancerby June 2, 2024PR Newswire
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meetingby June 2, 2024PR Newswire
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meetingby June 2, 2024PR Newswire
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLCby June 2, 2024PR Newswire
